A securities class action lawsuit has been filed against Avis Budget Group, alleging that defendants manipulated the market by triggering a short squeeze that inflated the stock price. The suit claims Pentwater Capital Management, a major shareholder, benefited from this scheme, causing significant losses to other investors when the truth emerged. Investors who bought Avis stock between February 2025 and April 2026 are encouraged to contact Bernstein Liebhard LLP to discuss their rights and possibly join the lawsuit. The firm is seeking a lead plaintiff by September 29, 2026, to represent the class in litigation.
Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a stron...
Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...
Duluth Holdings reported a strong Q2 earnings per share (EPS) of $0.50, far exceeding the consensus estimate of -$0.01, largely due to $0.44 per share from tariff refunds. Revenue reached $121.39 million, beating estimates but declining from the prev...
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. ...
